Treatment Approaches for Heavily Pretreated RRMM

Heavily Pretreated RRMM: Patient Assessment & Treatment Selection

Selinexor for Heavily Pretreated RRRMM

Targeting BCMA in Relapsed/Refractory Multiple Myeloma

DREAMM-2 Safety and Efficacy Data in RRMM

Targeting BCMA in RRMM: Ongoing Trials With Novel Therapies

Targeting BCMA in RRMM With CAR T-Cell Therapy

BCMA-Targeted Therapy in Multiple Myeloma

Videos

The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.

Multiple Myeloma: Targeting BCMA in the Heavily Pretreated Population

Assessing the Impact of TAILORx on Breast Cancer Management

Articles

ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.

Clinical Consult

Oncology Journal